Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brenda Hamberis

Physician Assistant Greenville, SC Physician Assistant

NPI 1174531453 CMS profile 10572930

3909 S Highway 14, Greenville, SC 29615

Open in the dashboard

General payments

$6,065

385 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brenda Hamberis of Greenville, SC is reported in the CMS Open Payments database as having received $6,065 across 385 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $527 44
2024 General $1,038 71
2023 General $1,665 101
2022 General $1,419 88
2021 General $1,416 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brenda Hamberis
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Brenda Hamberis were reported at $527. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Brenda Hamberis Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,416 $132 $37–$438 $132
2022 $1,419 $155 $48–$522 $149
2023 $1,665 $167 $52–$557 $160
2024 $1,038 $178 $55–$600 $164
2025 $527 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,282 123 payments
  2. Novo Nordisk Inc $770 53 payments
  3. Pfizer Inc. $329 19 payments
  4. Abbott Laboratories $308 15 payments
  5. Lilly USA, LLC $298 24 payments
  6. AstraZeneca Pharmaceuticals LP $291 6 payments
  7. Otsuka America Pharmaceutical, Inc. $257 13 payments
  8. Amgen Inc. $234 10 payments
  9. Janssen Pharmaceuticals, Inc $226 10 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $205 6 payments
  11. Other $1,864 106 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,065 385 payments
Products named General payments · program years 2021–2025
  1. Ozempic $570 34 payments
  2. VRAYLAR $555 38 payments
  3. RYBELSUS $507 34 payments
  4. UBRELVY $394 40 payments
  5. QULIPTA $274 34 payments
  6. REXULTI $257 13 payments
  7. NURTEC ODT $245 14 payments
  8. FARXIGA $237 2 payments
  9. XARELTO $226 10 payments
  10. XIFAXAN $205 6 payments
  11. Other $4,135 267 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

621

Median for Physician Assistant: 241

Drug cost

$18,087

Median for Physician Assistant: $4,110

Branded share of claims

15.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 13 $11,772
Albuterol Sulfate Hfa Albuterol Sulfate Brand 29 $803
Irbesartan Generic 12 $738
Rosuvastatin Calcium Generic 59 $536
Montelukast Sodium Generic 44 $438
Levothyroxine Sodium Generic 30 $368
Duloxetine Hcl Generic 12 $336
Metoprolol Succinate Generic 17 $291
Simvastatin Generic 12 $272
Sertraline Hcl Generic 16 $263

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$22,030

Of which drugs: $235

Medicare patients

168

Average age 74

Services billed

698

112 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 24%
Depression 24%
Osteoporosis 22%
Ischemic heart disease 21%
Chronic kidney disease 20%
Cancer 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 21 92 $67

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $195
$195 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $157
  • Lundbeck LLC $20
$178 — —
MOUNJARO
  • Lilly USA, LLC $63
$63 — —
NURTEC ODT
  • PFIZER INC. $59
$59 — —
UBRELVY
  • AbbVie, Inc. $58
$58 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

385 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record